Introduction
============

Breast reconstruction (BR), including autologous breast reconstruction (ABR) and prosthesic BR, has increased in incidence during the past decade. There is no doubt that BR greatly minimizes deformity and patients achieve a long-term esthetic result, thus enhancing their psychological well-being after mastectomy (MST).[@b1-ott-9-6829],[@b2-ott-9-6829] More importantly, BR has been established as an oncologically safe option for not only patients with early breast cancer (BC),[@b3-ott-9-6829] but also advanced BC in the previous studies.[@b4-ott-9-6829],[@b5-ott-9-6829] However, a small but significant number of patients develop local, regional, or distant recurrence after BR. Therefore, some literature had discussed about locoregional recurrence and distant recurrence after BR.[@b6-ott-9-6829]--[@b8-ott-9-6829] However, few studies reported about local recurrence (LR) after ABR.[@b9-ott-9-6829] The objective of this study was to evaluate incidence of LR following MST and ABR, related risk factors, and management of LR in our institution. Collectively, this study was designed to evaluate a single institution's experience with LR after post-MST BR using autologous flaps, which might be beneficial for the management of this select group of patients in the future.

Patients and methods
====================

From January 1999 to June 2014, 860 consecutive BC patients underwent BR in Fudan University Shanghai Cancer Center (FUSCC). Patients were excluded if they had pathological finding of sarcoma/angiosarcoma, phyllodes, inflammatory BC, or they did not undergo MST before BR. Taking at least 3-year follow-up time from December 2014 into account, we identified 397 patients who underwent MST and ABR from January 1999 to December 2011 at FUSCC with a potential follow-up period of more than 36 months. LR was strictly defined as pathologically proven BC recurring in the ipsilateral chest wall, skin, or subcutaneous tissue overlying the reconstructed breast. In our study, flaps used in ABR consisted of latissimus dorsi, pedicled transverse rectus abdominis myocutaneous flap (pTRAM) and free-TRAM, deep inferior epigastric perforator. None of the cases had MST and immediate tissue expander reconstruction. Whether to perform delayed or immediate, skin-sparing or nipple-sparing BR was left to the surgeon's discretion according to evaluation before or during surgery. The included patients underwent MST and ABR following a diagnosis of BC and all of them achieved negative margins postoperatively. The variables involved in our study included age, estrogen receptor, progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), clinical tumor stage, tumor type, tumor grade, lymphovascular invasion status, chemotherapy (CT), radiotherapy (RT), hormonal therapy (HT), pathological tumor size, and number of positive lymph nodes. Among them, tumor type was classified as two types: multifocal tumor and nonmultifocal tumor type; multifocal tumor was defined as Paget's disease or pathologically proven multifocal disease. Both follow-up and LR time was calculated from the time of MST. All the data with regard to patients as well as tumors were obtained from a prospectively maintained institutional database in FUSCC. This study was approved by the independent ethical committee/institutional review board of FUSCC (Shanghai Cancer Center Ethical Committee). Patient consent was not required due to the retrospective nature of the study

Life curve for LR-free survival was calculated using the Kaplan--Meier method. Difference in the survival between two groups was compared by log-rank test in the univariate analysis. Multivariate Cox regression model was applied in the multivariate analysis. LR-free survival was defined as the interval between the date of the operation and LR or the last follow-up. Only factors that turned out significant in univariate analysis could be tested in the multivariate analysis. All the statistics were performed with SPSS 18.0 (SPSS Inc., Chicago, IL, USA). Significance was considered as *P*\<0.05.

Results
=======

From January 1999 to December 2011, there were 397 MST patients who underwent ABR postoperatively. Of 397 patients, three patients presented with simultaneous bilateral BC, so ABRs were performed in 400 breasts of 397 patients during this period. Most breasts were reconstructed using latissimus dorsi flap with or without implant ([Table 1](#t1-ott-9-6829){ref-type="table"}). In the entire population, 16 and four cases underwent skin-sparing and nipple-sparing MST, respectively; moreover, only six patients had delayed BR.

Patients and tumor characteristics
----------------------------------

The mean age of all patients at surgery was 39 years (range 19--66 years), most patients were relatively young and therefore not in menopause. Mean size of tumor diameter was 2.7 cm (range 0.2--13.0 cm). All the tumor characteristics are shown in [Table 2](#t2-ott-9-6829){ref-type="table"}.

Follow-up and recurrence
------------------------

After a median follow-up of 3.6 years, eleven patients presented with LR after ABR. In all the eleven patients with LR, recurrences were first detected by physical examination, which mostly appeared as a palpable mass. Among them, chest wall was the most frequent site of LR (9/11). Besides, one recurrence on the nipple and another in the reconstructed breast were observed. Moreover, more than 50% of LR events occurred within the first 3 years of MST.

The median time to LR was 2.9 years (range 0.25--4.1 years). One-, 3-, and 5-year LR-free survival rates for the entire cohort were 99.7%, 98.1%, and 95.6%, respectively.

Risk factors and survival
-------------------------

In univariate analysis, the factors significantly associated with higher LR rate were negative estrogen receptor, multifocal tumor type, absence of HT, and tumor stage III ([Figures 1](#f1-ott-9-6829){ref-type="fig"}[](#f2-ott-9-6829){ref-type="fig"}[](#f3-ott-9-6829){ref-type="fig"}--[4](#f4-ott-9-6829){ref-type="fig"}). Patients with positive PR as well as post-MST CT tended to have higher LR-free survival compared with those without, but significant difference was not reached (*P*\>0.05).

HT strongly associated with estrogen receptor status, multivariate Cox regression analysis involving HT, tumor stage, and tumor type showed that HT (hazard ratio =5.48, *P*\<0.05), stage III (*P*\<0.05), and multifocal tumor type (hazard ratio =7.45, *P*\<0.05) were found to be independent risk factors of LR post-MST ABR ([Table 3](#t3-ott-9-6829){ref-type="table"}).

Treatment of LR
---------------

Besides first choice of excision of recurrent diseases (8/11), additional treatment included CT (9/11), RT (7/11), HT (5/11), and anti-HER-2 therapy (2/11) according to different situations. Implant/autologous flaps were removed in two of eight surgically treated patients.

Discussion
==========

With the increasing incidence of BR, more and more reports are paying attention to the recurrence of BC after BR, including autologous and prosthetic BR.[@b10-ott-9-6829],[@b11-ott-9-6829] Most of the previous studies focused on TRAM flap reconstruction for its wide acceptance as a standard method for ABR,[@b12-ott-9-6829]--[@b14-ott-9-6829] while ours was one of the few studies to have explored the development of LR of BC after the different kinds of ABRs, which consisted of 397 BC patients who underwent MST and ABR from January 1999 to December 2011 in our institution.

Based on the results of our study, we could confirm the oncological safety of BR following MST. After a median follow-up time of 3.6 years, which was well within the peak time of LR after MST reported by Crowe et al,[@b15-ott-9-6829] the LR rate of ABR patients after MST was only 2.8%. And this was also in line with analogous literature reporting that the rate of LR ranged from 2.3%[@b16-ott-9-6829] to 4.8%,[@b12-ott-9-6829] with at least 400 patients and a median follow-up time of 3 years.

All eleven LR cases that developed in our series were first detected by physical examination, and confirmed later with further imaging examinations and biopsies. This pattern of detection was exactly the same as several other studies;[@b12-ott-9-6829],[@b17-ott-9-6829],[@b18-ott-9-6829] however, inconclusively, the gold standard for the diagnosis of LR remains needle cytology or excision biopsy. The outcome strongly confirmed the primary importance of physical examination in the surveillance of LR for this specific target population of patients undergoing post-MST ABR, even though mammography, ultrasound, and magnetic resonance imaging may have advantages over physical examination under some circumstances.[@b19-ott-9-6829]--[@b21-ott-9-6829] On the other hand, it implied that the presence of flaps didn't delay the detection of recurrent lesions, which was also consistent with conclusions in previous studies.[@b6-ott-9-6829],[@b14-ott-9-6829]

In the univariate analysis, patients with positive PR, post-MST CT indeed obtained a higher 3-year LR-free survival than those without. The difference, however, was not statistically significant. It was possibly attributable to insufficient follow-up duration and limited number of recurrent events. However, a significant difference existed between patients with and without HT in both univariate (*P*=0.007) and multivariate analysis (*P*\<0.05). The 3-year LR-free survival of patients with HT was 100.0% while it reached 92.0% without HT. It was obvious that the application of HT greatly contributed to lower rate of local recurrence in this specific population. Our study also demonstrated that tumor stage III was also one of the strongest prognostic factors of LR for ABR patients. Similarly, a study by Medina-Franco et al reported that tumor stage II or III, tumor size \>2 cm, node-positive disease, and poor tumor differentiation were associated with higher LR rate.[@b22-ott-9-6829] In a recent study, Kneubil et al also found that BC subtypes, body mass index, and tumor size were independent prognostic factors for risk of locoregional recurrence after immediate BR.[@b23-ott-9-6829]

The LR of BC after post-MST ABR might be attributed to inadequate resection, undetected multifocal tumors, or absence of postoperative radiation. Interestingly enough, it was noted in our study that the difference in terms of LR-free survival between multifocal and nonmultifocal tumor was indeed the most significant. With univariate analysis, the patients with multifocal tumor experienced a 3-year LR-free survival of 85.9% while 3-year LR-free survival increased to 99.0% for other patients (*P*=0.004). Similarly, multivariate analysis also showed that with multifocal tumor, odds ratio was 7.45 (95% confidence interval =1.97, 28.21) for LR-free survival probability compared with the nonmultifocal group. This finding might result in surgeons cautiously choosing to perform ABRs in some patients with multifocal BC preoperatively, who achieved higher incidence of LR (8.3%) than patients with nonmultifocal BC (2.1%) in our series. These patients were most likely the potential candidates for ABR and possibly not suitable for partial MST. However, whether it could apply to a larger population of patients needs further demonstration in a randomized controlled trial.

It deserves to be mentioned that only one patient presenting with LR received post-MST RT, indicating that remaining ten cases might not have received adequate local treatment, whereas most of these patients had no indications for RT according to guidelines now. If we accurately identified this highly selected BR patients with higher risk of LR, we might have had better local control over these patients. However, this still remains unclear now, which demands further investigation in the future.

LR in the setting of previous MST and ABR can pose a management challenge for clinicians, for there is no standard treatment for these patients at present. However, salvage treatment options include surgery, CT, RT, HT, and targeted therapy. And flap is removed according to surgeons' experience or intraoperative evaluation whether recurrent BC has invaded reconstructed breast.

The strength of our study included strict definition of LR and a wide range of ABRs, which is relatively new compared to previous studies. Furthermore, we found that multifocal tumor type was associated with higher LR rate after MST and ABR. The limitation included a limited number of patients with LR postoperatively, mixture of noninvasive and invasive breast carcinoma, the retrospective nature of the study, and loss of follow-up to some extent.

Conclusion
==========

Post-MST, ABR is an oncologically safe procedure that does not compromise local control. Both univariate and multivariate analyses demonstrate that absence of HT, tumor stage III, and multifocal tumor type are associated with higher rate of LR after MST and ABR.

**Disclosure**

The authors report no conflicts of interest in this work.

![Kaplan--Meier local recurrence-free survival curve (different ER status). **Abbreviation:** ER, estrogen receptor.](ott-9-6829Fig1){#f1-ott-9-6829}

![Kaplan--Meier local recurrence-free survival curve (different tumor types).](ott-9-6829Fig2){#f2-ott-9-6829}

![Kaplan--Meier local recurrence-free survival curve (with or without HT).\
**Abbreviation:** HT, hormonal therapy.](ott-9-6829Fig3){#f3-ott-9-6829}

![Kaplan--Meier local recurrence-free survival curve (different tumor stage).](ott-9-6829Fig4){#f4-ott-9-6829}

###### 

Type of breast reconstructive procedures performed

  Breast reconstruction         N (%)
  ----------------------------- ------------
  LDF with or without implant   289 (72.2)
  pTRAM                         61 (15.3)
  Free-TRAM/DIEP                50 (12.5)

**Abbreviations:** DIEP, deep inferior epigastric perforator; LDF, latissimus dorsi flap; pTRAM, pedicled transverse rectus abdominis myocutaneous; TRAM, transverse rectus abdominis myocutaneous.

###### 

Demographic, clinical, and pathological characteristics of patients who underwent autologous breast reconstruction

  Characteristics               N (%)
  ----------------------------- -----------
  Total                         400 (100)
  Age (years)                   
   ≤40                          235
   \>40                         165
  cT                            
   T1                           218
   T2--4                        166
   Unknown                      16
  cN                            
   N0                           328
   N1--2                        72
  Clinical stage                
   I                            196
   II                           183
   III                          6
   Unknown                      15
  Histological grade            
   1 (IDC) + low (DCIS)         18
   2 (IDC) + median (DCIS)      200
   3 (IDC) + high (DCIS)        100
   Other                        19
   Unknown                      63
  LVSI                          
   Positive                     121
   Negative                     273
   Unknown                      6
  pT                            
   Tis                          56
   T1                           193
   T2                           118
   T3--4                        14
   Unknown                      19
  pN                            
   N0                           283
   N1                           82
   N2--3                        35
  ER                            
   Positive                     262
   Negative                     131
   Unknown                      7
  PR                            
   Positive                     232
   Negative                     146
   Unknown                      22
  HER2 (FISH)                   
   Positive                     82
   Negative                     295
   Unknown                      23
  Tumor type                    
   Multifocal disease type      35
   Nonmultifocal disease type   365
  HT                            
   Yes                          283
   No                           111
   Unknown                      6
  CT                            
   Yes                          311
   No                           78
   Unknown                      11
  RT                            
   Yes                          73
   No                           319
   Unknown                      8

**Abbreviations:** cN, clinical N stage; cT, clinical T stage; CT, chemotherapy; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HT, hormonal therapy; IDC, invasive ductal carcinoma; LVSI, lymphovascular invasion; pT, pathological T stage; pN, pathological N stage; PR, progesterone receptor; RT, radiotherapy.

###### 

Multivariate Cox regression analysis for risk factors and local recurrence

  Risk factors                             *P*-value   OR      95% CI
  ---------------------------------------- ----------- ------- --------------
  Without HT vs with HT                    \<0.05      5.48    1.37--21.95
  Stage III vs I                           \<0.05      51.82   6.71--400.15
  vs II                                    \<0.05      29.58   4.74--184.54
  Tumor type multifocal vs nonmultifocal   \<0.05      7.45    1.97--28.21

**Abbreviations:** CI, confidence interval; HT, hormonal therapy; OR, odds ratio.
